FDA Approves Darzalex Faspro for High-Risk Smoldering Multiple Myeloma

THURSDAY, Nov. 13, 2025-- The U.S. Food and Drug Administration has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) as a single-agent treatment for adult patients with high-risk smoldering multiple myeloma (HR-SMM).Darzalex Faspro is...